Shanghai Yueyang Integrated Medicine Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2019
NCT03823248
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Shanghai Yueyang Intergrated Medicnie Hospital,Shanghai | Yueyang Hospital of Integrated Traditional Chinese and Western Medicine

Active Ingredients

Drugs in Phase 3 Trials (2)

baidi quizhi (1 trial)

ju yin (1 trial)

Drugs in Phase 2 Trials (4)

folic acid (1 trial)

liuwei dihuang (1 trial)

moluodan (1 trial)

sanchi-tongshu (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Precancerous Conditions (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 6